Temporal variability in birth prevalence of congenital heart defects as recorded by a general birth defects registry

Bosi, G.; Garani, Giampaolo; Scorrano, M.; Calzolari, Elisa

doi:10.1067/mpd.2003.243

Cited by 49 publications

(61 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the decade preceding our study, an increase in the prevalence of CHD, particularly SIII, was reported in a number of European and other countries and attributed mainly to diagnostic factors. 22,24,26,31 The total prevalence of severe (SI/SII) nonchromosomal CHD cases in our population was 2.0 per 1000. These cases are more uniformly ascertained and were mainly diagnosed by the end of the first week of life, including a significant proportion of prenatally diagnosed cases.…”

Section: Discussionmentioning

confidence: 99%

“…Registries use multiple sources of information to ascertain cases in order to cover all types of cases (live birth [LB], late fetal death, and termination of pregnancy; surgical and nonsurgical; and with and without additional major non-CHD anomalies). Sources, depending on registry, 3,[21][22][23][24][25][26][27] include maternity, neonatal, and pediatric records; fetal medicine, cytogenetic, pathology, and medical genetics records; specialist services including pediatric cardiology; and hospital discharge and child health records. Twenty-one of the registries (covering 2.6 million births) included in the study ascertained cases of CHD diagnosed up to at least 1 year of life.…”

Section: Methodsmentioning

confidence: 99%

“…Perinatal mortality, mainly first week mortality, associated with CHD is significant in relation to overall perinatal mortality, despite a fall in infant mortality due to CHD during the 1990s. 23,26,38,39 In the EU in 2004, about one quarter of early neonatal deaths were due to congenital anomalies, and of these, in EUROCAT regions, 25% were CHD and a further 18% chromosomal with or without CHD. 1 The high nonchromosomal CHD perinatal mortality rate of 0.93 per 1000 births in the Ukraine is probably related to low treatment success.…”

Section: Dolk Et Al Congenital Heart Defects In Europe 845mentioning

confidence: 99%

See 2 more Smart Citations

Congenital Heart Defects in Europe

2011

View full text Add to dashboard Cite

Background— This study determines the prevalence of Congenital Heart Defects (CHD), diagnosed prenatally or in infancy, and fetal and perinatal mortality associated with CHD in Europe. Methods and Results— Data were extracted from the European Surveillance of Congenital Anomalies central database for 29 population-based congenital anomaly registries in 16 European countries covering 3.3 million births during the period 2000 to 2005. CHD cases (n=26 598) comprised live births, fetal deaths from 20 weeks gestation, and terminations of pregnancy for fetal anomaly (TOPFA). The average total prevalence of CHD was 8.0 per 1000 births, and live birth prevalence was 7.2 per 1000 births, varying between countries. The total prevalence of nonchromosomal CHD was 7.0 per 1000 births, of which 3.6% were perinatal deaths, 20% prenatally diagnosed, and 5.6% TOPFA. Severe nonchromosomal CHD (ie, excluding ventricular septal defects, atrial septal defects, and pulmonary valve stenosis) occurred in 2.0 per 1000 births, of which 8.1% were perinatal deaths, 40% were prenatally diagnosed, and 14% were TOPFA (TOPFA range between countries 0% to 32%). Live-born CHD associated with Down syndrome occurred in 0.5 per 1000 births, with >4-fold variation between countries. Conclusion— Annually in the European Union, we estimate 36 000 children are live born with CHD and 3000 who are diagnosed with CHD die as a TOFPA, late fetal death, or early neonatal death. Investing in primary prevention and pathogenetic research is essential to reduce this burden, as well as continuing to improve cardiac services from in utero to adulthood.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Dolk Et Al Congenital Heart Defects In Europe 845mentioning

confidence: 99%

See 1 more Smart Citation

Congenital Heart Defects in Europe

2011

View full text Add to dashboard Cite

show abstract

“…Furthermore, four of 1000 live births will be affected by severe congenital cardiac malformations, which account for 20% of neonatal deaths and up to 50% of infant deaths attributed to congenital anomalies (2,6). Nevertheless differences exist in the rates of prenatal diagnosis and termination of CHDs across populations, and through time (7)(8)(9), which has an impact on the live birth prevalence of the more severe cases of CHDs, particularly for hypo-plastic left heart syndrome (HLHS) and related morbidity and mortality (3,10). Counseling of parents has become increasingly essential, as the frequency of detecting of fetal abnormalities has increased.…”

Section: Introductionmentioning

confidence: 99%

Counseling and outcomes of antenatally diagnosed congenital heart anomalies in Turkey

Gedikbaşı¹,

Öztarhan²,

Yıldırım³

et al. 2011

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

ÖZETAmaç: Prenatal tanı almış, fetal kalp anomalilerinin, klinik sonuçları ve aile kararlarının değerlendirilmesi. Yöntemler: Prenatal doğumsal kalp anomali tanısı konmuş olgular (n=155), retrospektif yöntemle Allan ve Huggon'ın sınıflandırması doğrultu-sunda, Grup A (doğumsal kalp anomalisine eşlik eden ağır / ölümcül kalp dışı patoloji); Grup B1 (postnatal prognoz açısından düşük risk), Grup B2 (orta risk, düşük mortalite oranı ile uyumlu cerrahi mortalite) ve Grup B3 (yüksek risk-cerrahi sonrası için yüksek mortalite) olarak sınıflan-dırıldı. Ailelere verilen, danışma sonrası yenidoğan verileri, buna gebelik sonlandırması dahil edilmiştir ve 18 ay süreyle izlendi. Bulgular: Olguların 145'inin izlemi tam olarak gerçekleştirilmiştir. Otuz dokuz olguda (Grup A) eşlik eden ölümcül kalp dışı anomaliler saptanmış-tır ve bunların gebelik sonlandırılmasına karar verilmiştir; bu olgular istatistiksel değerlendirmeye alınmamıştır. Grup B3' teki olguların 20 tanesi de gebelik sonlandırmasına karar verdi. Diğer üç kalp anomalisi gruplarında, gebeliğin devamına karar veren ailelerde (Grup B1, n=37; Grup B2, n=12; Grup B3, n=37), 18 ayın sonunda sağkalım oranları sırasıyla %89.2, %66.7 ve %13.5 bulunmuştur. İstatistiksel verilerin değerlendirmesinde Student's t-test, Mann-Whitney U, Pearson's Ki-kare testi ve Fischer's exact Ki-kare testi uygulanmıştır. Sağkalım açısından 3 grupta istatistiksel anlamlılık saptanmıştır [Grup B3 ile Grup B1: p=0.0001; OR: 52.8 (12.9-214.5); Grup B3 ile Grup B2: p=0.0009; OR: 12.8 (2.8-58.9); Grup B2 ile Grup B1: p=0.087; OR: 4.12 (0.84-20.2)]. Sonuç: Uygulamalarımız ve istatistiksel sonuçlarımız, bu sınıflama sisteminin, doğumsal kalp anomalileri açısından ebeveynlere verilecek danış-mada etkili olduğunu gösterdi. ABSTRACTObjective: To determine the clinical outcomes and decisions of families of fetuses with prenatally-diagnosed cardiac abnormalities. Methods: Prenatally diagnosed cases (n=155) with congenital heart disease were retrospectively categorized according to the Allan-Huggon grading system: Group A (cardiac disease associated with severe / lethal extracardiac disease); Group B1 (low risk with a postnatal prognosis); Group B2 (moderate risk, amenable to surgical repair with a low mortality); and Group B3 (high risk, associated with high mortality after surgery). Neonatal outcomes, including termination of pregnancy, were recorded for 18 months of follow-up after counseling the parents. Student's t-test, Mann-Whitney U, Pearson's Chi-square test and Fischer's exact Chi-square test were used for statistical analyses. Results: One hundred forty-five cases completed follow up. Thirty-nine cases (Group A) were associated with extracardiac lethal defects and the pregnancies were terminated; these cases were excluded from statistical evaluation. Twenty parents in Group B3 opted also for termination. The survival rates of ongoing pregnancies after 18 months of follow-up between the three cardiac abnormality Groups (Group B1, n=37; Group B2, n=12; and Group B3, n=37) were 89.2%, 66.7%, and...

show abstract

“…There are reports pointing out the rising prevalence during recent years (2,3). The improvement in medicine and technology that has rapidly progressed in the past few years has brought more children with heart defects surviving to adulthood (4,5).…”

Section: Introductionmentioning

confidence: 99%

Early Rehabilitation of Children in Different Age Groups after Correction of Non-Cyanotic Congenital Heart Defects

Ćirović¹,

Nikolić²,

Petronić³

et al. 2014

Turk J Phys Med Rehab

View full text Add to dashboard Cite

ÖzetAmaç: Çalışmamızın amacı düzeltilmiş siyanotik olmayan konjenital kalp defekti (KKD) olan çocuk grubunda erken rehabilitasyon programı süre-sini ve böyle bir programın başlangıç zamanını bildirmek ve değerlendir-mek, ayrıca erken rehabilitasyon programındaki her bir tekniğin uygulanma oranını değerlendirmekti. Gereç ve Yöntemler: Ventriküler septal defekt (VSD), atriyal septal defekt (ASD) ve persistent duktus arteriozusu (PDA) olan 274 çocuğu değerlen-dirdik. Hastalar yaşa göre 3 gruba ayrıldı: Bir yaşından küçük çocuk grubu, bir ila üç yaş arası çocuk grubu, üç ila yedi yaş arası çocuk grubu. Üç tip erken rehabilitasyon tekniği değerlendirildi: kineziterapi, perküsyon drenaj ve vertikalizasyon. Bulgular: Kineziterapi ve perküsyon drenaj, VSD veya ASD'li her çocukta uygulanmaktadır, ancak PDA'lı çocuklarda, perküsyon drenaj bir hastada uygulanmadı. Erken rehabilitasyon programının süresi düzeltilmiş VSD'li çocuklar için 5-7 gün arasında, düzeltilmiş ASD'li çocuklar için 4-6 gün arasında ve düzeltilmiş PDA'lı çocuklar için 3-6 gün arasında idi. Sonuç: Erken rehabilitasyon, defekt düzeltilmesinden sonra ilk 2 gün için-de başlamalıdır. Düzeltilmiş siyanotik olmayan KKD'li çocuklarda erken rehabilitasyon programının süresi katılımcıların yaşından çok KKD tipine bağlıdır. Aynı durum bu programın başlangıcı için dönem tahmininde de geçerlidir. Anahtar Kelimeler: Konjenital kalp defektleri, kineziterapi, perküsyon drenaj, vertikalizasyon AbstractObjective: The aim of our study was to present and evaluate the duration of an early rehabilitation program and time for the beginning of such a program in a group of children with corrected non-cyanotic congenital heart defects (CHDs), as well to evaluate the proportion of implementation of each technique from the early rehabilitation program. Material and Methods: We evaluated 274 children with: ventricular septal defect (VSD), atrial septal defect (ASD), and persistent ductus arteriosus (DAP). Patients were classified into 3 groups due to age: group of children younger than 1 year of life, group of children between first and third year of life, and group of children between third and seventh year of life. Three types of early rehabilitation techniques were assessed: kinesitherapy, percussion drainage, and verticalization. Results: Kinesitherapy and percussion drainage were administered in every child with VSD or ASD, while for children with DAP, percussion drainage was not administered in 1 patient. Duration of the early rehabilitation program for children with corrected VSD was between 5-7 days, between 4-6 days for children with corrected ASD, and between 3-6 days for patients with corrected DAP. Conclusion: Early rehabilitation should start within the first 2 days after defect correction. Duration of the early rehabilitation program in children with corrected non-cyanotic CHD is more dependent on the type of CHD than on the age of participants. The same applies for the estimation of the period for the beginning of this program.

show abstract

Temporal variability in birth prevalence of congenital heart defects as recorded by a general birth defects registry

Cited by 49 publications

References 23 publications

Congenital Heart Defects in Europe

Congenital Heart Defects in Europe

Counseling and outcomes of antenatally diagnosed congenital heart anomalies in Turkey

Early Rehabilitation of Children in Different Age Groups after Correction of Non-Cyanotic Congenital Heart Defects

Contact Info

Product

Resources

About